{
  "symbol": "ELVN",
  "company_name": "Enliven Therapeutics Inc",
  "ir_website": "https://ir.enliventherapeutics.com/",
  "structured_data": [
    {
      "section_name": "News",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://ir.enliventherapeutics.com/news/press-releases",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Enliven Therapeutics Logo](/sites/g/files/knoqqb81321/themes/site/nir_pid7944/dist/images/logo.svg)](https://www.enliventherapeutics.com/) [](#)[](#)\n\n#  Press Releases \n\nYear All Years2024202320222020\n\n2024\n\nDate | Title | View  \n---|---|---  \nNovember 13, 2024  |  [Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update](/news-releases/news-release-details/enliven-therapeutics-reports-third-quarter-financial-results-and) |  [PDF Version](/node/9296/pdf)  \nNovember 7, 2024  |  [Enliven Therapeutics to Present at the Jefferies London Healthcare Conference](/news-releases/news-release-details/enliven-therapeutics-present-jefferies-london-healthcare) |  [PDF Version](/node/9286/pdf)  \nSeptember 28, 2024  |  [Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia](/news-releases/news-release-details/enliven-therapeutics-announces-positive-data-update-phase-1) |  [PDF Version](/node/9091/pdf)  \nSeptember 18, 2024  |  [Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML](/news-releases/news-release-details/enliven-therapeutics-announces-details-regarding-presentation) |  [PDF Version](/node/9076/pdf)  \nAugust 13, 2024  |  [Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update](/news-releases/news-release-details/enliven-therapeutics-reports-second-quarter-financial-results) |  [PDF Version](/node/9021/pdf)  \nMay 29, 2024  |  [Enliven Therapeutics to Present at Two Upcoming Investor Conferences](/news-releases/news-release-details/enliven-therapeutics-present-two-upcoming-investor-conferences-0) |  [PDF Version](/node/8791/pdf)  \nMay 14, 2024  |  [Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update](/news-releases/news-release-details/enliven-therapeutics-reports-first-quarter-financial-results-and) |  [PDF Version](/node/8706/pdf)  \nApril 11, 2024  |  [Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia](/news-releases/news-release-details/enliven-therapeutics-announces-positive-proof-concept-data-phase) |  [PDF Version](/node/8536/pdf)  \nApril 9, 2024  |  [Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors](/news-releases/news-release-details/enliven-therapeutics-appoints-dr-lori-kunkel-board-directors) |  [PDF Version](/node/8496/pdf)  \nMarch 28, 2024  |  [Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024](/news-releases/news-release-details/enliven-therapeutics-share-initial-proof-concept-data-phase-1) |  [PDF Version](/node/8451/pdf)  \n  \nDisplaying 1 - 10 of 13 \n\n[Print Page]()\n\n[Email Alerts](/ir-resources/email-alerts)\n\n[RSS Feeds](/rss-feeds)\n\n[Contact Us](/ir-resources/contact-us)\n"
        }
      ]
    },
    {
      "section_name": "Upcoming Events",
      "links": [
        {
          "title": "Jefferies London Healthcare Conference",
          "url": "https://wsw.com/webcast/jeff315/elvn/1857828",
          "content": "![Jefferies](/images/resources/jefferies20120920/images/mm_logo.png)\n\n  * [CONFERENCES](https://www.jefferies.com/OurFirm/ConferenceList/Investment-Conferences/159)\n  * [JEFFERIES HOME](https://www.jefferies.com/)\n\n\n\n# Jefferies London Healthcare Conference\n\n## November 19th - 21st, 2024\n\nTo register for the webcast, please enter your information in the form below.\n\nEvent: |  Jefferies London Healthcare Conference  \n---|---  \nPresentation: |  Enliven Therapeutics, Inc  \nTime: |  11/19/2024 9:30 AM (GMT)  \n  \nFirst Name* |  First name required  \n---|---  \nLast Name* |  First and last name cannot be the same. Last name required  \nCompany Name* |  Company name required  \nEmail* |  Email required Email is not valid  \n* Required Field  \n  \nYou must have cookies enabled in order to register for this event\n\n[![Summitcast](/images/resources/images/summitcast_logo_sm_black.png)](https://twstevents.com/divisions/summitcast)\n"
        },
        {
          "title": "ELVN-001 Initial Proof of Concept Data and the Evolving CML Landscape",
          "url": "https://elvn-001data-cmllandscape.open-exchange.net/registration",
          "content": "\n"
        }
      ]
    },
    {
      "section_name": "Presentations",
      "links": [
        {
          "title": "Enliven Company Overview",
          "url": "https://ir.enliventherapeutics.com/static-files/9c927814-9a92-4fea-a827-7f04ebfb6a40",
          "content": "\n"
        }
      ]
    }
  ]
}